CleftGeneDB-Search

Gene: TIPARP

Basic information

Tag	Content
Uniprot ID	Q7Z3E1; D3DNK6; Q68CY9; Q86VP4; Q9Y4P7;
Entrez ID	25976
Genbank protein ID	AAH50350.2; CAB45747.2; EAW78725.1; EAW78728.1; CAH18441.1; CAD97929.1;
Genbank nucleotide ID	NM_001184717.1; NM_001184718.1; NM_015508.4;
Ensembl protein ID	ENSP00000418757; ENSP00000438345; ENSP00000295924; ENSP00000420612;
Ensembl nucleotide ID	ENSG00000163659
Gene name	Protein mono-ADP-ribosyltransferase TIPARP
Gene symbol	TIPARP
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate, aspartate and cysteine residues on target proteins (PubMed:23275542, PubMed:25043379, PubMed:30373764). Acts as a negative regulator of AHR by mediating mono-ADP-ribosylation of AHR, leading to inhibit transcription activator activity of AHR (PubMed:23275542, PubMed:30373764).
Sequence	MEMETTEPEP DCVVQPPSPP DDFSCQMRLS EKITPLKTCF KKKDQKRLGT GTLRSLRPIL 60 NTLLESGSLD GVFRSRNQST DENSLHEPMM KKAMEINSSC PPAENNMSVL IPDRTNVGDQ 120 IPEAHPSTEA PERVVPIQDH SFPSETLSGT VADSTPAHFQ TDLLHPVSSD VPTSPDCLDK 180 VIDYVPGIFQ ENSFTIQYIL DTSDKLSTEL FQDKSEEASL DLVFELVNQL QYHTHQENGI 240 EICMDFLQGT CIYGRDCLKH HTVLPYHWQI KRTTTQKWQS VFNDSQEHLE RFYCNPENDR 300 MRMKYGGQEF WADLNAMNVY ETTEFDQLRR LSTPPSSNVN SIYHTVWKFF CRDHFGWREY 360 PESVIRLIEE ANSRGLKEVR FMMWNNHYIL HNSFFRREIK RRPLFRSCFI LLPYLQTLGG 420 VPTQAPPPLE ATSSSQIICP DGVTSANFYP ETWVYMHPSQ DFIQVPVSAE DKSYRIIYNL 480 FHKTVPEFKY RILQILRVQN QFLWEKYKRK KEYMNRKMFG RDRIINERHL FHGTSQDVVD 540 GICKHNFDPR VCGKHATMFG QGSYFAKKAS YSHNFSKKSS KGVHFMFLAK VLTGRYTMGS 600 HGMRRPPPVN PGSVTSDLYD SCVDNFFEPQ IFVIFNDDQS YPYFVIQYEE VSNTVSI 657

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	TIPARP	102182170	A0A452F6F5		Capra hircus	Prediction	More>>
1:1 ortholog	TIPARP	25976	Q7Z3E1		Homo sapiens	Prediction	More>>
1:1 ortholog	Tiparp	99929	Q8C1B2	CPO	Mus musculus	Publication	More>>
1:1 ortholog	TIPARP	460801	H2QNM7		Pan troglodytes	Prediction	More>>
1:1 ortholog	TIPARP	100626111	I3LQD6		Sus scrofa	Prediction	More>>
1:1 ortholog	TIPARP		G1T8C7		Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Tiparp	310467	D3ZMH5		Rattus norvegicus	Prediction	More>>
1:1 ortholog	tiparp		F8W3Q5		Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1469957050	p.Glu2Lys	missense variant	-	NC_000003.12:g.156677701G>A	gnomAD
rs1156974645	p.Met3Val	missense variant	-	NC_000003.12:g.156677704A>G	gnomAD
rs868515771	p.Met3Ile	missense variant	-	NC_000003.12:g.156677706G>A	TOPMed,gnomAD
NCI-TCGA novel	p.Thr5Ser	missense variant	-	NC_000003.12:g.156677711C>G	NCI-TCGA
rs781581358	p.Thr6Ile	missense variant	-	NC_000003.12:g.156677714C>T	ExAC,gnomAD
rs1401304502	p.Thr6Ala	missense variant	-	NC_000003.12:g.156677713A>G	gnomAD
rs770701311	p.Glu7Lys	missense variant	-	NC_000003.12:g.156677716G>A	ExAC,TOPMed,gnomAD
rs778899104	p.Pro8Thr	missense variant	-	NC_000003.12:g.156677719C>A	ExAC,gnomAD
rs546558483	p.Glu9Gln	missense variant	-	NC_000003.12:g.156677722G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs771541243	p.Pro10Leu	missense variant	-	NC_000003.12:g.156677726C>T	ExAC,gnomAD
rs760946108	p.Asp11Glu	missense variant	-	NC_000003.12:g.156677730C>A	ExAC,TOPMed,gnomAD
rs774941696	p.Asp11His	missense variant	-	NC_000003.12:g.156677728G>C	ExAC,gnomAD
rs1232121372	p.Val13Ile	missense variant	-	NC_000003.12:g.156677734G>A	gnomAD
rs776153131	p.Val14Leu	missense variant	-	NC_000003.12:g.156677737G>C	ExAC,gnomAD
rs776153131	p.Val14Met	missense variant	-	NC_000003.12:g.156677737G>A	ExAC,gnomAD
rs762231689	p.Pro19Ser	missense variant	-	NC_000003.12:g.156677752C>T	ExAC,gnomAD
rs765576832	p.Asp21Gly	missense variant	-	NC_000003.12:g.156677759A>G	ExAC,TOPMed,gnomAD
rs140846531	p.Glu31Gln	missense variant	-	NC_000003.12:g.156677788G>C	1000Genomes,ExAC,gnomAD
NCI-TCGA novel	p.Glu31Gly	missense variant	-	NC_000003.12:g.156677789A>G	NCI-TCGA
rs1196989993	p.Ile33Thr	missense variant	-	NC_000003.12:g.156677795T>C	TOPMed
rs755118316	p.Ile33Val	missense variant	-	NC_000003.12:g.156677794A>G	ExAC,TOPMed,gnomAD
rs1165514996	p.Pro35Gln	missense variant	-	NC_000003.12:g.156677801C>A	gnomAD
NCI-TCGA novel	p.Pro35Leu	missense variant	-	NC_000003.12:g.156677801C>T	NCI-TCGA
COSM4457315	p.Pro35Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156677800C>T	NCI-TCGA Cosmic
rs767777633	p.Leu36Phe	missense variant	-	NC_000003.12:g.156677805G>T	ExAC,gnomAD
rs1490831364	p.Cys39Arg	missense variant	-	NC_000003.12:g.156677812T>C	TOPMed
rs1330694297	p.Cys39Tyr	missense variant	-	NC_000003.12:g.156677813G>A	gnomAD
rs369539588	p.Phe40Ser	missense variant	-	NC_000003.12:g.156677816T>C	ESP,TOPMed
rs200349044	p.Lys42Glu	missense variant	-	NC_000003.12:g.156677821A>G	1000Genomes
rs144427222	p.Lys42Arg	missense variant	-	NC_000003.12:g.156677822A>G	ESP,ExAC,TOPMed,gnomAD
rs1413853265	p.Lys43Arg	missense variant	-	NC_000003.12:g.156677825A>G	gnomAD
NCI-TCGA novel	p.Lys43Asn	missense variant	-	NC_000003.12:g.156677826G>T	NCI-TCGA
rs757054333	p.Asp44Val	missense variant	-	NC_000003.12:g.156677828A>T	ExAC,TOPMed,gnomAD
rs778614554	p.Asp44Glu	missense variant	-	NC_000003.12:g.156677829T>G	ExAC,gnomAD
rs1314626498	p.Asp44Tyr	missense variant	-	NC_000003.12:g.156677827G>T	TOPMed
COSM4114795	p.Arg47Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156677837G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Thr52Ser	missense variant	-	NC_000003.12:g.156677851A>T	NCI-TCGA
rs1281827005	p.Leu53Val	missense variant	-	NC_000003.12:g.156677854C>G	TOPMed
rs1346761723	p.Leu60Ile	missense variant	-	NC_000003.12:g.156677875T>A	TOPMed
rs1194403954	p.Asn61Ser	missense variant	-	NC_000003.12:g.156677879A>G	gnomAD
rs758283343	p.Thr62Ser	missense variant	-	NC_000003.12:g.156677882C>G	ExAC,gnomAD
rs1255712431	p.Leu64Ile	missense variant	-	NC_000003.12:g.156677887C>A	gnomAD
rs1331911830	p.Leu69Pro	missense variant	-	NC_000003.12:g.156677903T>C	gnomAD
NCI-TCGA novel	p.Leu69Arg	missense variant	-	NC_000003.12:g.156677903T>G	NCI-TCGA
rs776332548	p.Asp70Gly	missense variant	-	NC_000003.12:g.156677906A>G	ExAC,gnomAD
rs373659607	p.Val72Ala	missense variant	-	NC_000003.12:g.156677912T>C	ESP
rs1367037499	p.Ser75Tyr	missense variant	-	NC_000003.12:g.156677921C>A	gnomAD
NCI-TCGA novel	p.Ser75Cys	missense variant	-	NC_000003.12:g.156677921C>G	NCI-TCGA
rs547183561	p.Gln78Arg	missense variant	-	NC_000003.12:g.156677930A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1414170718	p.Ser79Thr	missense variant	-	NC_000003.12:g.156677933G>C	TOPMed
rs1433869787	p.Thr80Ala	missense variant	-	NC_000003.12:g.156677935A>G	gnomAD
rs1427423976	p.Asp81Tyr	missense variant	-	NC_000003.12:g.156677938G>T	TOPMed
rs763428665	p.Glu82Asp	missense variant	-	NC_000003.12:g.156677943G>T	ExAC,gnomAD
COSM1484785	p.Glu82Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156677941G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ser84Cys	missense variant	-	NC_000003.12:g.156677947A>T	NCI-TCGA
rs1356995828	p.His86Arg	missense variant	-	NC_000003.12:g.156677954A>G	gnomAD
rs766929028	p.Pro88Ser	missense variant	-	NC_000003.12:g.156677959C>T	ExAC,TOPMed,gnomAD
rs766929028	p.Pro88Thr	missense variant	-	NC_000003.12:g.156677959C>A	ExAC,TOPMed,gnomAD
rs1185862685	p.Met89Arg	missense variant	-	NC_000003.12:g.156677963T>G	TOPMed
rs568594097	p.Met89Val	missense variant	-	NC_000003.12:g.156677962A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1225949830	p.Met94Arg	missense variant	-	NC_000003.12:g.156677978T>G	gnomAD
NCI-TCGA novel	p.Glu95Lys	missense variant	-	NC_000003.12:g.156677980G>A	NCI-TCGA
rs767546856	p.Ile96Val	missense variant	-	NC_000003.12:g.156677983A>G	ExAC,TOPMed,gnomAD
rs1296705490	p.Asn97His	missense variant	-	NC_000003.12:g.156677986A>C	gnomAD
COSM729509	p.Ser99Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000003.12:g.156677993C>G	NCI-TCGA Cosmic
rs1210646750	p.Pro101Thr	missense variant	-	NC_000003.12:g.156677998C>A	gnomAD
rs750161818	p.Asn105Thr	missense variant	-	NC_000003.12:g.156678011A>C	ExAC,gnomAD
rs758193176	p.Asn106Ser	missense variant	-	NC_000003.12:g.156678014A>G	ExAC,gnomAD
rs761597601	p.Met107Val	missense variant	-	NC_000003.12:g.156678016A>G	gnomAD
rs747004966	p.Met107Thr	missense variant	-	NC_000003.12:g.156678017T>C	ExAC,gnomAD
rs1324727307	p.Ile111Leu	missense variant	-	NC_000003.12:g.156678028A>C	TOPMed
NCI-TCGA novel	p.Pro112Ser	missense variant	-	NC_000003.12:g.156678031C>T	NCI-TCGA
rs377432950	p.Asp113Asn	missense variant	-	NC_000003.12:g.156678034G>A	ESP,TOPMed
rs1171574601	p.Arg114Gly	missense variant	-	NC_000003.12:g.156678037A>G	TOPMed,gnomAD
rs1270890303	p.Thr115Arg	missense variant	-	NC_000003.12:g.156678041C>G	TOPMed
rs1364672501	p.Thr115Ser	missense variant	-	NC_000003.12:g.156678040A>T	TOPMed
rs1466292816	p.Asn116Ser	missense variant	-	NC_000003.12:g.156678044A>G	gnomAD
rs780604647	p.Asn116Asp	missense variant	-	NC_000003.12:g.156678043A>G	ExAC,TOPMed,gnomAD
rs868513491	p.Val117Ala	missense variant	-	NC_000003.12:g.156678047T>C	gnomAD
rs1338961044	p.Gly118Glu	missense variant	-	NC_000003.12:g.156678050G>A	TOPMed
NCI-TCGA novel	p.Gly118Arg	missense variant	-	NC_000003.12:g.156678049G>A	NCI-TCGA
rs747722067	p.Asp119Asn	missense variant	-	NC_000003.12:g.156678052G>A	ExAC,TOPMed,gnomAD
rs1298308351	p.Asp119Gly	missense variant	-	NC_000003.12:g.156678053A>G	gnomAD
rs1298308351	p.Asp119Val	missense variant	-	NC_000003.12:g.156678053A>T	gnomAD
rs1233983933	p.Ile121Met	missense variant	-	NC_000003.12:g.156678060A>G	gnomAD
rs201782670	p.Ile121Thr	missense variant	-	NC_000003.12:g.156678059T>C	1000Genomes,ExAC,TOPMed,gnomAD
rs201782670	p.Ile121Lys	missense variant	-	NC_000003.12:g.156678059T>A	1000Genomes,ExAC,TOPMed,gnomAD
rs772928271	p.Pro122Leu	missense variant	-	NC_000003.12:g.156678062C>T	ExAC,gnomAD
rs1301783177	p.Pro122Thr	missense variant	-	NC_000003.12:g.156678061C>A	gnomAD
rs1260370769	p.Glu123Lys	missense variant	-	NC_000003.12:g.156678064G>A	gnomAD
rs1248543218	p.His125Arg	missense variant	-	NC_000003.12:g.156678071A>G	gnomAD
rs774980008	p.His125Asp	missense variant	-	NC_000003.12:g.156678070C>G	ExAC,gnomAD
rs757036019	p.Pro126Ser	missense variant	-	NC_000003.12:g.156678073C>T	TOPMed,gnomAD
rs1191510420	p.Ser127Pro	missense variant	-	NC_000003.12:g.156678076T>C	gnomAD
NCI-TCGA novel	p.Glu132Lys	missense variant	-	NC_000003.12:g.156678091G>A	NCI-TCGA
rs569197742	p.Arg133Ter	stop gained	-	NC_000003.12:g.156678094C>T	1000Genomes,TOPMed,gnomAD
rs147956353	p.Arg133Leu	missense variant	-	NC_000003.12:g.156678095G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs569197742	p.Arg133Gly	missense variant	-	NC_000003.12:g.156678094C>G	1000Genomes,TOPMed,gnomAD
rs147956353	p.Arg133Gln	missense variant	-	NC_000003.12:g.156678095G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1361728193	p.Val135Ile	missense variant	-	NC_000003.12:g.156678100G>A	gnomAD
rs140235972	p.Pro136Gln	missense variant	-	NC_000003.12:g.156678104C>A	ESP,ExAC,TOPMed,gnomAD
rs558453273	p.Pro136Ser	missense variant	-	NC_000003.12:g.156678103C>T	1000Genomes,ExAC,gnomAD
rs140235972	p.Pro136Arg	missense variant	-	NC_000003.12:g.156678104C>G	ESP,ExAC,TOPMed,gnomAD
rs1461451634	p.Gln138Arg	missense variant	-	NC_000003.12:g.156678110A>G	TOPMed
rs1251155796	p.Asp139Val	missense variant	-	NC_000003.12:g.156678113A>T	TOPMed
rs1188346646	p.His140Asp	missense variant	-	NC_000003.12:g.156678115C>G	TOPMed,gnomAD
rs1056511062	p.His140Arg	missense variant	-	NC_000003.12:g.156678116A>G	TOPMed,gnomAD
rs1188346646	p.His140Asn	missense variant	-	NC_000003.12:g.156678115C>A	TOPMed,gnomAD
rs1056511062	p.His140Pro	missense variant	-	NC_000003.12:g.156678116A>C	TOPMed,gnomAD
rs570398140	p.His140Gln	missense variant	-	NC_000003.12:g.156678117C>A	1000Genomes,ExAC,gnomAD
rs754124618	p.Phe142Ser	missense variant	-	NC_000003.12:g.156678122T>C	ExAC,gnomAD
rs762723611	p.Pro143Ala	missense variant	-	NC_000003.12:g.156678124C>G	ExAC,gnomAD
rs766210307	p.Ser144Pro	missense variant	-	NC_000003.12:g.156678127T>C	ExAC,gnomAD
rs1435480214	p.Glu145Gly	missense variant	-	NC_000003.12:g.156678131A>G	gnomAD
rs1306496410	p.Thr146Ile	missense variant	-	NC_000003.12:g.156678134C>T	gnomAD
rs752087020	p.Leu147His	missense variant	-	NC_000003.12:g.156678137T>A	ExAC,gnomAD
rs371094017	p.Leu147Phe	missense variant	-	NC_000003.12:g.156678136C>T	ESP,ExAC,TOPMed
NCI-TCGA novel	p.Leu147ProPheSerTerUnkUnk	frameshift	-	NC_000003.12:g.156678133_156678134insC	NCI-TCGA
rs1268917045	p.Ser148Arg	missense variant	-	NC_000003.12:g.156678141T>A	TOPMed,gnomAD
NCI-TCGA novel	p.Ser148Ile	missense variant	-	NC_000003.12:g.156678140G>T	NCI-TCGA
rs1297430382	p.Gly149Glu	missense variant	-	NC_000003.12:g.156678143G>A	TOPMed
rs755720358	p.Thr150Met	missense variant	-	NC_000003.12:g.156678146C>T	ExAC,gnomAD
rs534523851	p.Ala152Ser	missense variant	-	NC_000003.12:g.156678151G>T	1000Genomes,ExAC,gnomAD
rs375315846	p.Ser154Cys	missense variant	-	NC_000003.12:g.156678158C>G	ESP,ExAC,TOPMed,gnomAD
rs779381790	p.Thr155Ala	missense variant	-	NC_000003.12:g.156678160A>G	ExAC,TOPMed,gnomAD
rs746258116	p.Pro156Leu	missense variant	-	NC_000003.12:g.156678164C>T	ExAC,gnomAD
rs772403493	p.His158Arg	missense variant	-	NC_000003.12:g.156678170A>G	ExAC,gnomAD
rs1459421210	p.Phe159Ser	missense variant	-	NC_000003.12:g.156678173T>C	gnomAD
rs200200707	p.Phe159Leu	missense variant	-	NC_000003.12:g.156678174C>G	TOPMed
COSM3589313	p.Gln160Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000003.12:g.156678175C>T	NCI-TCGA Cosmic
rs994568863	p.Thr161Ser	missense variant	-	NC_000003.12:g.156678179C>G	TOPMed
rs776070977	p.Leu163Val	missense variant	-	NC_000003.12:g.156678184C>G	ExAC,TOPMed,gnomAD
rs776070977	p.Leu163Ile	missense variant	-	NC_000003.12:g.156678184C>A	ExAC,TOPMed,gnomAD
rs1222441797	p.Leu164Ser	missense variant	-	NC_000003.12:g.156678188T>C	TOPMed
rs1371447209	p.Val167Phe	missense variant	-	NC_000003.12:g.156678196G>T	gnomAD
rs776811846	p.Ser168Leu	missense variant	-	NC_000003.12:g.156678200C>T	ExAC,gnomAD
rs765471373	p.Asp170Val	missense variant	-	NC_000003.12:g.156678206A>T	ExAC,gnomAD
rs751301965	p.Pro175Leu	missense variant	-	NC_000003.12:g.156678221C>T	ExAC,TOPMed,gnomAD
rs759385620	p.Leu178Val	missense variant	-	NC_000003.12:g.156678229T>G	ExAC,gnomAD
rs767287641	p.Asp179Gly	missense variant	-	NC_000003.12:g.156678233A>G	ExAC,TOPMed,gnomAD
rs372015234	p.Lys180Arg	missense variant	-	NC_000003.12:g.156678236A>G	ESP,ExAC,TOPMed,gnomAD
rs372015234	p.Lys180Thr	missense variant	-	NC_000003.12:g.156678236A>C	ESP,ExAC,TOPMed,gnomAD
rs755559962	p.Val181Ile	missense variant	-	NC_000003.12:g.156678238G>A	ExAC,gnomAD
rs140976569	p.Ile182Val	missense variant	-	NC_000003.12:g.156678241A>G	ESP
rs1182371185	p.Tyr184Cys	missense variant	-	NC_000003.12:g.156678248A>G	gnomAD
rs777469638	p.Tyr184Asp	missense variant	-	NC_000003.12:g.156678247T>G	ExAC,gnomAD
NCI-TCGA novel	p.Pro186Ser	missense variant	-	NC_000003.12:g.156678253C>T	NCI-TCGA
NCI-TCGA novel	p.Pro186Leu	missense variant	-	NC_000003.12:g.156678254C>T	NCI-TCGA
NCI-TCGA novel	p.Glu191Ter	stop gained	-	NC_000003.12:g.156678268G>T	NCI-TCGA
NCI-TCGA novel	p.Asn192LysPheSerTerUnkUnk	frameshift	-	NC_000003.12:g.156678273C>-	NCI-TCGA
NCI-TCGA novel	p.Asn192ThrPheSerTerUnkUnk	frameshift	-	NC_000003.12:g.156678269A>-	NCI-TCGA
rs1473913455	p.Ser193Gly	missense variant	-	NC_000003.12:g.156678274A>G	gnomAD
rs1189500859	p.Phe194Ser	missense variant	-	NC_000003.12:g.156678278T>C	gnomAD
rs150223955	p.Ile196Val	missense variant	-	NC_000003.12:g.156678283A>G	ESP,TOPMed,gnomAD
rs1170168644	p.Gln197Arg	missense variant	-	NC_000003.12:g.156678287A>G	gnomAD
rs1165006151	p.Tyr198His	missense variant	-	NC_000003.12:g.156678289T>C	TOPMed
rs746154012	p.Tyr198Cys	missense variant	-	NC_000003.12:g.156678290A>G	ExAC,TOPMed,gnomAD
rs1308823808	p.Ile199Thr	missense variant	-	NC_000003.12:g.156678293T>C	gnomAD
NCI-TCGA novel	p.Leu200Met	missense variant	-	NC_000003.12:g.156678295C>A	NCI-TCGA
rs772553375	p.Asp201His	missense variant	-	NC_000003.12:g.156678298G>C	ExAC,gnomAD
rs747599850	p.Thr202Pro	missense variant	-	NC_000003.12:g.156678301A>C	ExAC,gnomAD
rs747599850	p.Thr202Ala	missense variant	-	NC_000003.12:g.156678301A>G	ExAC,gnomAD
rs768586185	p.Ser203Thr	missense variant	-	NC_000003.12:g.156678305G>C	ExAC,gnomAD
rs1293361007	p.Leu210Val	missense variant	-	NC_000003.12:g.156678325C>G	gnomAD
rs1343992691	p.Gln212Leu	missense variant	-	NC_000003.12:g.156678332A>T	TOPMed,gnomAD
rs1343992691	p.Gln212Arg	missense variant	-	NC_000003.12:g.156678332A>G	TOPMed,gnomAD
rs201843889	p.Asp213Asn	missense variant	-	NC_000003.12:g.156678334G>A	ESP,ExAC,TOPMed,gnomAD
rs1279139901	p.Glu217Asp	missense variant	-	NC_000003.12:g.156678348G>C	gnomAD
rs1484506901	p.Ala218Ser	missense variant	-	NC_000003.12:g.156678349G>T	gnomAD
rs773424243	p.Leu222Phe	missense variant	-	NC_000003.12:g.156678361C>T	ExAC,TOPMed,gnomAD
rs759242586	p.Val223Met	missense variant	-	NC_000003.12:g.156678364G>A	ExAC,gnomAD
NCI-TCGA novel	p.Val223Leu	missense variant	-	NC_000003.12:g.156678364G>C	NCI-TCGA
rs758347957	p.Glu225Gln	missense variant	-	NC_000003.12:g.156678370G>C	ExAC,TOPMed,gnomAD
COSM4114796	p.Thr234Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156678397A>C	NCI-TCGA Cosmic
rs983254095	p.His235Arg	missense variant	-	NC_000003.12:g.156678401A>G	TOPMed
rs1336416903	p.Glu237Ala	missense variant	-	NC_000003.12:g.156678407A>C	gnomAD
rs140486151	p.Asn238Asp	missense variant	-	NC_000003.12:g.156678409A>G	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly239Glu	missense variant	-	NC_000003.12:g.156678413G>A	NCI-TCGA
COSM264041	p.Ile242Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156678423T>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Cys243Tyr	missense variant	-	NC_000003.12:g.156678425G>A	NCI-TCGA
rs1430147291	p.Met244Val	missense variant	-	NC_000003.12:g.156678427A>G	TOPMed,gnomAD
rs1317726110	p.Met244Thr	missense variant	-	NC_000003.12:g.156678428T>C	TOPMed
rs753340986	p.Gln248Arg	missense variant	-	NC_000003.12:g.156678440A>G	ExAC,gnomAD
rs756834863	p.Gly249Asp	missense variant	-	NC_000003.12:g.156678443G>A	ExAC,TOPMed,gnomAD
rs764978014	p.Thr250Ile	missense variant	-	NC_000003.12:g.156678446C>T	ExAC,TOPMed,gnomAD
rs764978014	p.Thr250Ser	missense variant	-	NC_000003.12:g.156678446C>G	ExAC,TOPMed,gnomAD
rs201976652	p.Ile252Met	missense variant	-	NC_000003.12:g.156678453T>G	TOPMed,gnomAD
rs758666395	p.Arg255Gly	missense variant	-	NC_000003.12:g.156678460A>G	ExAC,gnomAD
NCI-TCGA novel	p.Arg255Lys	missense variant	-	NC_000003.12:g.156678461G>A	NCI-TCGA
rs779765422	p.Asp256Tyr	missense variant	-	NC_000003.12:g.156678463G>T	ExAC,TOPMed,gnomAD
rs747363738	p.Asp256Gly	missense variant	-	NC_000003.12:g.156678464A>G	ExAC,gnomAD
rs1466691731	p.Asp256Glu	missense variant	-	NC_000003.12:g.156678465T>G	gnomAD
NCI-TCGA novel	p.Cys257LysThrValPhe	insertion	-	NC_000003.12:g.156678468_156678469insAAAACTGTTTTC	NCI-TCGA
rs1189598175	p.Leu258Phe	missense variant	-	NC_000003.12:g.156678471G>T	gnomAD
rs1286559879	p.Lys259Arg	missense variant	-	NC_000003.12:g.156678473A>G	TOPMed
rs781670937	p.Ile270Met	missense variant	-	NC_000003.12:g.156678507C>G	ExAC,gnomAD
rs1426168303	p.Lys271Gln	missense variant	-	NC_000003.12:g.156678508A>C	gnomAD
rs746495291	p.Arg272Ser	missense variant	-	NC_000003.12:g.156678513G>C	TOPMed
rs748156388	p.Arg272Gly	missense variant	-	NC_000003.12:g.156678511A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Arg272LysPheSerTerUnkUnk	frameshift	-	NC_000003.12:g.156678507_156678508insA	NCI-TCGA
rs1489734415	p.Thr273Ser	missense variant	-	NC_000003.12:g.156678514A>T	gnomAD
rs1479652371	p.Thr273Ile	missense variant	-	NC_000003.12:g.156678515C>T	TOPMed
NCI-TCGA novel	p.Thr275LeuPheSerTerUnkUnk	frameshift	-	NC_000003.12:g.156678520A>-	NCI-TCGA
NCI-TCGA novel	p.Trp278Arg	missense variant	-	NC_000003.12:g.156678529T>C	NCI-TCGA
rs1438383637	p.Ser280Asn	missense variant	-	NC_000003.12:g.156678536G>A	TOPMed,gnomAD
rs1428394274	p.Phe282Val	missense variant	-	NC_000003.12:g.156678541T>G	TOPMed
rs145662613	p.Asn283Ile	missense variant	-	NC_000003.12:g.156678545A>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs145662613	p.Asn283Ser	missense variant	-	NC_000003.12:g.156678545A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
COSM1040373	p.Asp284Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156678547G>T	NCI-TCGA Cosmic
rs947722121	p.Ser285Phe	missense variant	-	NC_000003.12:g.156678551C>T	gnomAD
NCI-TCGA novel	p.His288Gln	missense variant	-	NC_000003.12:g.156678561C>A	NCI-TCGA
COSM264042	p.Glu290Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156678565G>A	NCI-TCGA Cosmic
rs775306797	p.Cys294Gly	missense variant	-	NC_000003.12:g.156678577T>G	ExAC,gnomAD
rs138118991	p.Asn295Asp	missense variant	-	NC_000003.12:g.156678580A>G	1000Genomes,ESP,ExAC,gnomAD
NCI-TCGA novel	p.Asn295Ser	missense variant	-	NC_000003.12:g.156678581A>G	NCI-TCGA
rs149538633	p.Asp299Gly	missense variant	-	NC_000003.12:g.156678593A>G	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Met303Val	missense variant	-	NC_000003.12:g.156678604A>G	NCI-TCGA
rs776778193	p.Lys304Asn	missense variant	-	NC_000003.12:g.156678609G>T	ExAC,TOPMed,gnomAD
rs35768405	p.Tyr305Cys	missense variant	-	NC_000003.12:g.156678611A>G	ESP,ExAC,TOPMed,gnomAD
rs35768405	p.Tyr305Ser	missense variant	-	NC_000003.12:g.156678611A>C	ESP,ExAC,TOPMed,gnomAD
rs1390490421	p.Gly307Glu	missense variant	-	NC_000003.12:g.156694022G>A	gnomAD
rs1390490421	p.Gly307Glu	missense variant	-	NC_000003.12:g.156694022G>A	NCI-TCGA
rs1240885572	p.Glu309Ala	missense variant	-	NC_000003.12:g.156694028A>C	TOPMed
COSM3427267	p.Glu309Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000003.12:g.156694027G>T	NCI-TCGA Cosmic
rs1173472969	p.Asp313Glu	missense variant	-	NC_000003.12:g.156694041T>G	gnomAD
rs1379031614	p.Ala316Val	missense variant	-	NC_000003.12:g.156694049C>T	gnomAD
rs1466086841	p.Met317Leu	missense variant	-	NC_000003.12:g.156694051A>C	gnomAD
rs768539321	p.Val319Met	missense variant	-	NC_000003.12:g.156694057G>A	ExAC,gnomAD
rs768539321	p.Val319Leu	missense variant	-	NC_000003.12:g.156694057G>C	ExAC,gnomAD
rs769711462	p.Tyr320Cys	missense variant	-	NC_000003.12:g.156694061A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu321Asp	missense variant	-	NC_000003.12:g.156694065A>C	NCI-TCGA
rs773024103	p.Thr323Asn	missense variant	-	NC_000003.12:g.156694070C>A	ExAC,gnomAD
NCI-TCGA novel	p.Glu324Ter	stop gained	-	NC_000003.12:g.156694072G>T	NCI-TCGA
rs762517684	p.Gln327Lys	missense variant	-	NC_000003.12:g.156694081C>A	ExAC,gnomAD
rs770403066	p.Gln327His	missense variant	-	NC_000003.12:g.156694083A>C	ExAC,TOPMed,gnomAD
rs762517684	p.Gln327Glu	missense variant	-	NC_000003.12:g.156694081C>G	ExAC,gnomAD
NCI-TCGA novel	p.Arg329Gln	missense variant	-	NC_000003.12:g.156694088G>A	NCI-TCGA
rs1210445105	p.Ser332Cys	missense variant	-	NC_000003.12:g.156694097C>G	gnomAD
rs761032073	p.Ser336Phe	missense variant	-	NC_000003.12:g.156694109C>T	ExAC
rs1467830652	p.Ser336Ala	missense variant	-	NC_000003.12:g.156694108T>G	TOPMed,gnomAD
NCI-TCGA novel	p.Ser337Arg	missense variant	-	NC_000003.12:g.156694113C>A	NCI-TCGA
rs148252230	p.Asn338Ser	missense variant	-	NC_000003.12:g.156694115A>G	ESP,ExAC,TOPMed,gnomAD
rs148252230	p.Asn338Ser	missense variant	-	NC_000003.12:g.156694115A>G	NCI-TCGA
rs1036522422	p.Asn340Ser	missense variant	-	NC_000003.12:g.156694121A>G	NCI-TCGA
rs1036522422	p.Asn340Ser	missense variant	-	NC_000003.12:g.156694121A>G	-
rs1409042958	p.Ser341Cys	missense variant	-	NC_000003.12:g.156694124C>G	gnomAD
rs200857296	p.Ile342Val	missense variant	-	NC_000003.12:g.156694126A>G	ExAC,TOPMed,gnomAD
COSM1420232	p.Ile342ThrPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000003.12:g.156694125_156694128TATT>-	NCI-TCGA Cosmic
rs200119519	p.Val346Leu	missense variant	-	NC_000003.12:g.156694138G>C	1000Genomes,ExAC,gnomAD
COSM3783672	p.Val346Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156694138G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Lys348Thr	missense variant	-	NC_000003.12:g.156694145A>C	NCI-TCGA
rs1457691071	p.Phe349Cys	missense variant	-	NC_000003.12:g.156694148T>G	gnomAD
NCI-TCGA novel	p.His354Tyr	missense variant	-	NC_000003.12:g.156694162C>T	NCI-TCGA
rs750560844	p.Arg358Thr	missense variant	-	NC_000003.12:g.156694175G>C	ExAC,gnomAD
rs1425278368	p.Glu359Ala	missense variant	-	NC_000003.12:g.156694178A>C	gnomAD
NCI-TCGA novel	p.Glu359Asp	missense variant	-	NC_000003.12:g.156694179G>T	NCI-TCGA
rs141280180	p.Pro361Ala	missense variant	-	NC_000003.12:g.156694183C>G	ESP,ExAC,TOPMed,gnomAD
rs1387504652	p.Pro361Arg	missense variant	-	NC_000003.12:g.156694184C>G	gnomAD
rs141280180	p.Pro361Ser	missense variant	-	NC_000003.12:g.156694183C>T	ESP,ExAC,TOPMed,gnomAD
rs150739414	p.Glu362Lys	missense variant	-	NC_000003.12:g.156694186G>A	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu362Asp	missense variant	-	NC_000003.12:g.156694188G>T	NCI-TCGA
rs139609776	p.Ile365Val	missense variant	-	NC_000003.12:g.156695871A>G	ESP,ExAC,TOPMed,gnomAD
rs745377501	p.Arg366Gln	missense variant	-	NC_000003.12:g.156695875G>A	NCI-TCGA
rs745377501	p.Arg366Gln	missense variant	-	NC_000003.12:g.156695875G>A	ExAC,gnomAD
rs778830481	p.Arg366Gly	missense variant	-	NC_000003.12:g.156695874C>G	ExAC,gnomAD
rs745377501	p.Arg366Leu	missense variant	-	NC_000003.12:g.156695875G>T	ExAC,gnomAD
rs1331757567	p.Glu369Ter	stop gained	-	NC_000003.12:g.156695883G>T	TOPMed
rs1390721044	p.Glu369Ala	missense variant	-	NC_000003.12:g.156695884A>C	TOPMed,gnomAD
NCI-TCGA novel	p.Glu370Ter	stop gained	-	NC_000003.12:g.156695886G>T	NCI-TCGA
COSM4114798	p.Glu370Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156695888A>C	NCI-TCGA Cosmic
rs1168397565	p.Ala371Thr	missense variant	-	NC_000003.12:g.156695889G>A	gnomAD
rs143409745	p.Asn372Ser	missense variant	-	NC_000003.12:g.156695893A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs746682952	p.Asn372His	missense variant	-	NC_000003.12:g.156695892A>C	ExAC,TOPMed,gnomAD
rs143409745	p.Asn372Thr	missense variant	-	NC_000003.12:g.156695893A>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs762251916	p.Ser373Pro	missense variant	-	NC_000003.12:g.156695895T>C	ExAC,TOPMed,gnomAD
rs1358581953	p.Ser373Phe	missense variant	-	NC_000003.12:g.156695896C>T	gnomAD
rs773919171	p.Arg374Gln	missense variant	-	NC_000003.12:g.156695899G>A	ExAC,TOPMed,gnomAD
rs201159091	p.Arg374Trp	missense variant	-	NC_000003.12:g.156695898C>T	ExAC,TOPMed,gnomAD
rs1379855861	p.Gly375Cys	missense variant	-	NC_000003.12:g.156695901G>T	TOPMed,gnomAD
rs763107741	p.Leu376Pro	missense variant	-	NC_000003.12:g.156695905T>C	ExAC,TOPMed,gnomAD
rs766612770	p.Glu378Ala	missense variant	-	NC_000003.12:g.156695911A>C	ExAC,TOPMed,gnomAD
rs1302605426	p.Arg380Gln	missense variant	-	NC_000003.12:g.156695917G>A	TOPMed,gnomAD
COSM4733817	p.Arg380Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000003.12:g.156695916C>T	NCI-TCGA Cosmic
rs147143306	p.Phe381Ser	missense variant	-	NC_000003.12:g.156695920T>C	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Met383Ile	missense variant	-	NC_000003.12:g.156695927G>A	NCI-TCGA
rs552678860	p.Trp384Cys	missense variant	-	NC_000003.12:g.156695930G>T	gnomAD
rs1380989916	p.Asn385Asp	missense variant	-	NC_000003.12:g.156695931A>G	gnomAD
rs1309888637	p.Asn386Lys	missense variant	-	NC_000003.12:g.156695936C>G	gnomAD
rs1239696007	p.Tyr388Cys	missense variant	-	NC_000003.12:g.156695941A>G	gnomAD
rs767797746	p.Ile389Val	missense variant	-	NC_000003.12:g.156695943A>G	ExAC,TOPMed,gnomAD
rs1437753614	p.Leu390Arg	missense variant	-	NC_000003.12:g.156695947T>G	TOPMed,gnomAD
rs753513614	p.His391Arg	missense variant	-	NC_000003.12:g.156695950A>G	ExAC,gnomAD
rs757147574	p.Asn392Ser	missense variant	-	NC_000003.12:g.156695953A>G	ExAC,TOPMed,gnomAD
rs757874481	p.Arg396Gly	missense variant	-	NC_000003.12:g.156695964A>G	ExAC,TOPMed,gnomAD
rs779496951	p.Arg397Ser	missense variant	-	NC_000003.12:g.156695969A>C	ExAC,TOPMed,gnomAD
rs1221148557	p.Arg397Gly	missense variant	-	NC_000003.12:g.156695967A>G	TOPMed
rs746549290	p.Glu398Asp	missense variant	-	NC_000003.12:g.156695972G>C	NCI-TCGA
rs746549290	p.Glu398Asp	missense variant	-	NC_000003.12:g.156695972G>C	ExAC,gnomAD
rs768134379	p.Ile399Thr	missense variant	-	NC_000003.12:g.156695974T>C	ExAC,TOPMed,gnomAD
rs768134379	p.Ile399Arg	missense variant	-	NC_000003.12:g.156695974T>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ile399Val	missense variant	-	NC_000003.12:g.156695973A>G	NCI-TCGA
NCI-TCGA novel	p.Arg402Ter	stop gained	-	NC_000003.12:g.156695982A>T	NCI-TCGA
rs1362884365	p.Pro403Ser	missense variant	-	NC_000003.12:g.156695985C>T	TOPMed
rs770336627	p.Phe405Leu	missense variant	-	NC_000003.12:g.156695993C>A	ExAC,gnomAD
rs771589802	p.Arg406Leu	missense variant	-	NC_000003.12:g.156695995G>T	ExAC,TOPMed,gnomAD
rs771589802	p.Arg406His	missense variant	-	NC_000003.12:g.156695995G>A	ExAC,TOPMed,gnomAD
rs17854621	p.Arg406Ser	missense variant	-	NC_000003.12:g.156695994C>A	ExAC,gnomAD
rs17854621	p.Arg406Ser	missense variant	-	NC_000003.12:g.156695994C>A	UniProt,dbSNP
VAR_027155	p.Arg406Ser	missense variant	-	NC_000003.12:g.156695994C>A	UniProt
rs17854621	p.Arg406Cys	missense variant	-	NC_000003.12:g.156695994C>T	NCI-TCGA,NCI-TCGA Cosmic
rs17854621	p.Arg406Cys	missense variant	-	NC_000003.12:g.156695994C>T	ExAC,gnomAD
rs771589802	p.Arg406His	missense variant	-	NC_000003.12:g.156695995G>A	NCI-TCGA,NCI-TCGA Cosmic
rs1435577851	p.Phe409Ile	missense variant	-	NC_000003.12:g.156696003T>A	gnomAD
rs774240678	p.Phe409Tyr	missense variant	-	NC_000003.12:g.156696004T>A	ExAC,gnomAD
rs140142843	p.Leu412Phe	missense variant	-	NC_000003.12:g.156696012C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1278786503	p.Leu412His	missense variant	-	NC_000003.12:g.156696013T>A	gnomAD
rs1137515	p.Leu418Phe	missense variant	-	NC_000003.12:g.156703428C>T	NCI-TCGA,NCI-TCGA Cosmic
rs1162604065	p.Val421Phe	missense variant	-	NC_000003.12:g.156703437G>T	gnomAD
NCI-TCGA novel	p.Val421Ile	missense variant	-	NC_000003.12:g.156703437G>A	NCI-TCGA
rs749686048	p.Pro422Ser	missense variant	-	NC_000003.12:g.156703440C>T	ExAC,TOPMed,gnomAD
rs749686048	p.Pro422Thr	missense variant	-	NC_000003.12:g.156703440C>A	ExAC,TOPMed,gnomAD
rs749686048	p.Pro422Ala	missense variant	-	NC_000003.12:g.156703440C>G	ExAC,TOPMed,gnomAD
rs200460123	p.Ala425Pro	missense variant	-	NC_000003.12:g.156703449G>C	ESP,ExAC,TOPMed,gnomAD
rs772247182	p.Ala425Gly	missense variant	-	NC_000003.12:g.156703450C>G	ExAC,gnomAD
rs1289740413	p.Pro426Ser	missense variant	-	NC_000003.12:g.156703452C>T	gnomAD
rs760849853	p.Pro428Arg	missense variant	-	NC_000003.12:g.156703459C>G	ExAC,gnomAD
rs774571724	p.Pro428Ser	missense variant	-	NC_000003.12:g.156703458C>T	ExAC,TOPMed,gnomAD
rs1202254748	p.Leu429Val	missense variant	-	NC_000003.12:g.156703461C>G	TOPMed
rs764320963	p.Ala431Val	missense variant	-	NC_000003.12:g.156703468C>T	ExAC,gnomAD
rs1482892663	p.Ser435Pro	missense variant	-	NC_000003.12:g.156703479T>C	gnomAD
rs1276018525	p.Gly442Glu	missense variant	-	NC_000003.12:g.156703501G>A	TOPMed
NCI-TCGA novel	p.Val443Ile	missense variant	-	NC_000003.12:g.156703503G>A	NCI-TCGA
rs201451219	p.Asn447His	missense variant	-	NC_000003.12:g.156703515A>C	1000Genomes,ExAC,TOPMed,gnomAD
rs201451219	p.Asn447Asp	missense variant	-	NC_000003.12:g.156703515A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1389152742	p.Phe448Leu	missense variant	-	NC_000003.12:g.156703518T>C	gnomAD
rs912606472	p.Tyr449His	missense variant	-	NC_000003.12:g.156703521T>C	TOPMed
rs1334810026	p.Val454Phe	missense variant	-	NC_000003.12:g.156703536G>T	TOPMed
rs752284660	p.Met456Val	missense variant	-	NC_000003.12:g.156703542A>G	ExAC,gnomAD
rs1471030817	p.Gln460Arg	missense variant	-	NC_000003.12:g.156703555A>G	TOPMed
rs1334055498	p.Ile463Met	missense variant	-	NC_000003.12:g.156703565C>G	gnomAD
rs942689983	p.Ile463Val	missense variant	-	NC_000003.12:g.156703563A>G	TOPMed,gnomAD
COSM479629	p.Val465Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156703570T>A	NCI-TCGA Cosmic
rs1450634187	p.Pro466Arg	missense variant	-	NC_000003.12:g.156703573C>G	gnomAD
rs777573979	p.Val467Leu	missense variant	-	NC_000003.12:g.156703575G>C	ExAC,TOPMed,gnomAD
rs777573979	p.Val467Ile	missense variant	-	NC_000003.12:g.156703575G>A	ExAC,TOPMed,gnomAD
rs757698240	p.Lys472Glu	missense variant	-	NC_000003.12:g.156703590A>G	ExAC,gnomAD
rs1226375510	p.Ser473Asn	missense variant	-	NC_000003.12:g.156703594G>A	gnomAD
rs150068199	p.Arg475Trp	missense variant	-	NC_000003.12:g.156703599C>T	ESP,ExAC,gnomAD
COSM5892927	p.Arg475Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156703600G>A	NCI-TCGA Cosmic
rs145315559	p.Asn479Ser	missense variant	-	NC_000003.12:g.156703612A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs370596394	p.Glu487Asp	missense variant	-	NC_000003.12:g.156703637G>T	ESP,ExAC,TOPMed,gnomAD
rs747102891	p.Lys489Gln	missense variant	-	NC_000003.12:g.156703641A>C	ExAC,gnomAD
rs776902281	p.Leu493Phe	missense variant	-	NC_000003.12:g.156703655G>T	ExAC,gnomAD
rs762719514	p.Gln494His	missense variant	-	NC_000003.12:g.156703658G>T	ExAC,gnomAD
rs774124108	p.Leu496Ser	missense variant	-	NC_000003.12:g.156703663T>C	ExAC,gnomAD
NCI-TCGA novel	p.Glu505Asp	missense variant	-	NC_000003.12:g.156703691G>T	NCI-TCGA
rs184863885	p.Lys506Arg	missense variant	-	NC_000003.12:g.156703693A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs752190385	p.Lys508Arg	missense variant	-	NC_000003.12:g.156703699A>G	ExAC,TOPMed
NCI-TCGA novel	p.Lys510Ile	missense variant	-	NC_000003.12:g.156704686A>T	NCI-TCGA
NCI-TCGA novel	p.Lys511Thr	missense variant	-	NC_000003.12:g.156704689A>C	NCI-TCGA
rs140631438	p.Glu512Asp	missense variant	-	NC_000003.12:g.156704693A>T	ESP,ExAC,TOPMed,gnomAD
rs1261037745	p.Phe519Ser	missense variant	-	NC_000003.12:g.156704713T>C	gnomAD
rs1488040531	p.Gly520Asp	missense variant	-	NC_000003.12:g.156704716G>A	gnomAD
rs199568062	p.Arg521His	missense variant	-	NC_000003.12:g.156704719G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs146547620	p.Arg521Ser	missense variant	-	NC_000003.12:g.156704718C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs146547620	p.Arg521Cys	missense variant	-	NC_000003.12:g.156704718C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1321219131	p.Asp522Gly	missense variant	-	NC_000003.12:g.156704722A>G	TOPMed
rs963750734	p.Asp522Tyr	missense variant	-	NC_000003.12:g.156704721G>T	gnomAD
rs745663982	p.Asp522Glu	missense variant	-	NC_000003.12:g.156704723C>G	ExAC,gnomAD
rs145937401	p.Arg523Gly	missense variant	-	NC_000003.12:g.156704724A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs775538386	p.Arg523Lys	missense variant	-	NC_000003.12:g.156704725G>A	ExAC,gnomAD
rs145937401	p.Arg523Trp	missense variant	-	NC_000003.12:g.156704724A>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1390872537	p.Ile524Val	missense variant	-	NC_000003.12:g.156704727A>G	TOPMed
NCI-TCGA novel	p.Ile525Met	missense variant	-	NC_000003.12:g.156704732A>G	NCI-TCGA
rs150170944	p.Asn526Ser	missense variant	-	NC_000003.12:g.156704734A>G	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Arg528Thr	missense variant	-	NC_000003.12:g.156704740G>C	NCI-TCGA
NCI-TCGA novel	p.His532Asn	missense variant	-	NC_000003.12:g.156704751C>A	NCI-TCGA
rs776226052	p.Ser535Cys	missense variant	-	NC_000003.12:g.156704761C>G	ExAC,gnomAD
rs1183347333	p.Asp537Val	missense variant	-	NC_000003.12:g.156704767A>T	TOPMed
rs1291975962	p.Asp537His	missense variant	-	NC_000003.12:g.156704766G>C	gnomAD
rs1477929991	p.Lys544Arg	missense variant	-	NC_000003.12:g.156704788A>G	TOPMed
rs764935974	p.Asn546Ser	missense variant	-	NC_000003.12:g.156704794A>G	ExAC,gnomAD
NCI-TCGA novel	p.Arg550Gln	missense variant	-	NC_000003.12:g.156704806G>A	NCI-TCGA
rs763349428	p.His555Arg	missense variant	-	NC_000003.12:g.156704821A>G	ExAC,gnomAD
rs368152871	p.Met558Thr	missense variant	-	NC_000003.12:g.156704830T>C	ESP,ExAC,TOPMed,gnomAD
rs766769030	p.Met558Val	missense variant	-	NC_000003.12:g.156704829A>G	ExAC,TOPMed,gnomAD
rs1242403472	p.Met558Ile	missense variant	-	NC_000003.12:g.156704831G>A	gnomAD
NCI-TCGA novel	p.Phe559Leu	missense variant	-	NC_000003.12:g.156704832T>C	NCI-TCGA
rs973547078	p.Gln561His	missense variant	-	NC_000003.12:g.156704840A>T	TOPMed,gnomAD
COSM3427268	p.Ala566Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156704853G>A	NCI-TCGA Cosmic
rs755428022	p.Asn574Tyr	missense variant	-	NC_000003.12:g.156704877A>T	ExAC,TOPMed,gnomAD
rs1438174539	p.Ser576Ala	missense variant	-	NC_000003.12:g.156704883T>G	TOPMed
COSM5540390	p.Ser576Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156704884C>T	NCI-TCGA Cosmic
rs1204016670	p.Lys577Glu	missense variant	-	NC_000003.12:g.156704886A>G	gnomAD
COSM445853	p.Lys577Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156704888G>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ser579Phe	missense variant	-	NC_000003.12:g.156704893C>T	NCI-TCGA
rs1331122196	p.Ser580Pro	missense variant	-	NC_000003.12:g.156704895T>C	TOPMed
rs1319292966	p.Gly582Ala	missense variant	-	NC_000003.12:g.156704902G>C	TOPMed
rs752819159	p.Val583Asp	missense variant	-	NC_000003.12:g.156704905T>A	ExAC,gnomAD
rs1455252651	p.Phe585Leu	missense variant	-	NC_000003.12:g.156704910T>C	TOPMed
NCI-TCGA novel	p.Ala589Ser	missense variant	-	NC_000003.12:g.156704922G>T	NCI-TCGA
rs1163198135	p.Thr593Met	missense variant	-	NC_000003.12:g.156704935C>T	gnomAD
rs1168206881	p.Arg595Lys	missense variant	-	NC_000003.12:g.156704941G>A	gnomAD
rs749512926	p.Thr597Ala	missense variant	-	NC_000003.12:g.156704946A>G	ExAC,TOPMed,gnomAD
rs771313745	p.Met598Leu	missense variant	-	NC_000003.12:g.156704949A>C	ExAC,TOPMed,gnomAD
rs771313745	p.Met598Val	missense variant	-	NC_000003.12:g.156704949A>G	ExAC,TOPMed,gnomAD
rs746816452	p.Met598Thr	missense variant	-	NC_000003.12:g.156704950T>C	ExAC,gnomAD
rs1316971743	p.Ser600Thr	missense variant	-	NC_000003.12:g.156704956G>C	gnomAD
rs1394066979	p.Ser600Cys	missense variant	-	NC_000003.12:g.156704955A>T	gnomAD
rs761369679	p.His601Tyr	missense variant	-	NC_000003.12:g.156704958C>T	ExAC,TOPMed,gnomAD
rs1174463849	p.Gly602Ala	missense variant	-	NC_000003.12:g.156704962G>C	TOPMed
COSM4398877	p.Arg604Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156704968G>A	NCI-TCGA Cosmic
rs762552988	p.Arg605Ser	missense variant	-	NC_000003.12:g.156704972G>T	ExAC,gnomAD
rs762552988	p.Arg605Ser	missense variant	-	NC_000003.12:g.156704972G>C	ExAC,gnomAD
rs267599664	p.Pro606Leu	missense variant	-	NC_000003.12:g.156704974C>T	-
NCI-TCGA novel	p.Pro606His	missense variant	-	NC_000003.12:g.156704974C>A	NCI-TCGA
NCI-TCGA novel	p.Pro607Leu	missense variant	-	NC_000003.12:g.156704977C>T	NCI-TCGA
rs759897350	p.Val609Ile	missense variant	-	NC_000003.12:g.156704982G>A	ExAC,TOPMed,gnomAD
rs759897350	p.Val609Leu	missense variant	-	NC_000003.12:g.156704982G>C	ExAC,TOPMed,gnomAD
rs540401885	p.Asn610Ser	missense variant	-	NC_000003.12:g.156704986A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs753194812	p.Asn610Asp	missense variant	-	NC_000003.12:g.156704985A>G	ExAC,gnomAD
rs764041948	p.Pro611Thr	missense variant	-	NC_000003.12:g.156704988C>A	ExAC,gnomAD
rs1229894784	p.Gly612Val	missense variant	-	NC_000003.12:g.156704992G>T	TOPMed,gnomAD
rs1229894784	p.Gly612Asp	missense variant	-	NC_000003.12:g.156704992G>A	TOPMed,gnomAD
rs1276262331	p.Ser613Gly	missense variant	-	NC_000003.12:g.156704994A>G	TOPMed
rs1411701037	p.Thr615Ala	missense variant	-	NC_000003.12:g.156705000A>G	gnomAD
rs757500372	p.Asp617Asn	missense variant	-	NC_000003.12:g.156705006G>A	ExAC,gnomAD
NCI-TCGA novel	p.Gln630His	missense variant	-	NC_000003.12:g.156705047G>T	NCI-TCGA
rs1291859416	p.Ile634Val	missense variant	-	NC_000003.12:g.156705057A>G	gnomAD
rs1291859416	p.Ile634Leu	missense variant	-	NC_000003.12:g.156705057A>C	gnomAD
NCI-TCGA novel	p.Asp637Tyr	missense variant	-	NC_000003.12:g.156705066G>T	NCI-TCGA
COSM4114802	p.Tyr641Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000003.12:g.156705079A>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Tyr643IlePheSerTerUnk	frameshift	-	NC_000003.12:g.156705083_156705084insA	NCI-TCGA
NCI-TCGA novel	p.Tyr643Cys	missense variant	-	NC_000003.12:g.156705085A>G	NCI-TCGA
rs781163882	p.Phe644Cys	missense variant	-	NC_000003.12:g.156705088T>G	ExAC,gnomAD
rs1366765234	p.Ile646Val	missense variant	-	NC_000003.12:g.156705093A>G	TOPMed
NCI-TCGA novel	p.Gln647Ter	stop gained	-	NC_000003.12:g.156705096C>T	NCI-TCGA
rs772548229	p.Ser652Gly	missense variant	-	NC_000003.12:g.156705111A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ser652IlePheSerTerUnkUnk	frameshift	-	NC_000003.12:g.156705111_156705112insTAAAG	NCI-TCGA
rs772548229	p.Ser652Arg	missense variant	-	NC_000003.12:g.156705111A>C	ExAC,TOPMed,gnomAD
rs748808261	p.Asn653Ser	missense variant	-	NC_000003.12:g.156705115A>G	ExAC,gnomAD
rs1266929320	p.Thr654Ala	missense variant	-	NC_000003.12:g.156705117A>G	TOPMed,gnomAD
rs138664121	p.Ser656Thr	missense variant	-	NC_000003.12:g.156705123T>A	ESP,ExAC,TOPMed,gnomAD
rs138664121	p.Ser656Pro	missense variant	-	NC_000003.12:g.156705123T>C	ESP,ExAC,TOPMed,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001430	Adenoma	group	BEFREE
C0001973	Alcoholic Intoxication, Chronic	disease	BEFREE;PSYGENET
C0002395	Alzheimer's Disease	disease	BEFREE
C0002622	Amnesia	disease	BEFREE
C0002736	Amyotrophic Lateral Sclerosis	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004096	Asthma	disease	BEFREE
C0004364	Autoimmune Diseases	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0006826	Malignant Neoplasms	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007124	Noninfiltrating Intraductal Carcinoma	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE
C0007682	CNS disorder	group	BEFREE
C0007847	Malignant tumor of cervix	disease	BEFREE
C0009375	Colonic Neoplasms	group	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0010054	Coronary Arteriosclerosis	disease	BEFREE
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE
C0015695	Fatty Liver	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0019158	Hepatitis	disease	BEFREE
C0019159	Hepatitis A	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE
C0020456	Hyperglycemia	disease	BEFREE
C0020538	Hypertensive disease	group	BEFREE
C0024117	Chronic Obstructive Airway Disease	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025202	melanoma	disease	BEFREE
C0025289	Meningitis	disease	BEFREE
C0026769	Multiple Sclerosis	disease	BEFREE
C0027051	Myocardial Infarction	disease	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE;GWASCAT;GWASDB
C0032580	Adenomatous Polyposis Coli	disease	BEFREE
C0032584	polyps	phenotype	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE
C0038454	Cerebrovascular accident	group	BEFREE
C0151744	Myocardial Ischemia	disease	BEFREE
C0205851	Germ cell tumor	group	BEFREE
C0206664	Teratocarcinoma	disease	BEFREE
C0235950	Zinc deficiency	disease	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0241397	Triphalangeal thumb	disease	BEFREE
C0278883	Metastatic melanoma	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0302592	Cervix carcinoma	disease	BEFREE
C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0369183	Erythrocyte Mean Corpuscular Hemoglobin Test	phenotype	GWASDB
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0521657	Allergic encephalitis	disease	BEFREE
C0524851	Neurodegenerative Disorders	group	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0553580	Ewings sarcoma	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	GWASCAT;GWASDB
C0678222	Breast Carcinoma	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0850572	Adenomatous polyp of colon	disease	BEFREE
C0919267	ovarian neoplasm	disease	CTD_human
C1140680	Malignant neoplasm of ovary	disease	BEFREE;CTD_human
C1257915	Intestinal Polyposis	disease	BEFREE
C1261473	Sarcoma	group	BEFREE
C1261502	Finding of Mean Corpuscular Hemoglobin	phenotype	GWASDB
C1306459	Primary malignant neoplasm	group	BEFREE
C1378703	Renal carcinoma	disease	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE
C2711227	Steatohepatitis	disease	BEFREE
C4048328	cervical cancer	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0003950	NAD+ ADP-ribosyltransferase activity	IDA
GO:0035326	cis-regulatory region binding	IDA
GO:0046872	metal ion binding	IEA
GO:1990404	protein ADP-ribosylase activity	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0001570	vasculogenesis	IEA
GO:0001822	kidney development	IEA
GO:0006471	protein ADP-ribosylation	IDA
GO:0008209	androgen metabolic process	IEA
GO:0008210	estrogen metabolic process	IEA
GO:0008585	female gonad development	IEA
GO:0009791	post-embryonic development	IEA
GO:0010629	negative regulation of gene expression	IMP
GO:0030097	hemopoiesis	IEA
GO:0045732	positive regulation of protein catabolic process	IMP
GO:0048008	platelet-derived growth factor receptor signaling pathway	IEA
GO:0048705	skeletal system morphogenesis	IEA
GO:0048745	smooth muscle tissue development	IEA
GO:0060021	roof of mouth development	IEA
GO:0060325	face morphogenesis	IEA
GO:0070213	protein auto-ADP-ribosylation	IDA
GO:0071407	cellular response to organic cyclic compound	IDA
GO:0140289	protein mono-ADP-ribosylation	IDA
GO:1904612	response to 2,3,7,8-tetrachlorodibenzodioxine	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005634	nucleus	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence

Drugs and compounds information

ID	Drug Name	Action	PubMed
C051452	1,2,3,7,8-pentachlorodibenzo-p-dioxin	1,2,3,7,8-pentachlorodibenzo-p-dioxin results in increased expression of TIPARP mRNA	29738842
C576882	1-(2-trifluoromethoxyphenyl)-2-nitroethanone	1-(2-trifluoromethoxyphenyl)-2-nitroethanone results in increased expression of TIPARP mRNA	25596134
C033310	1,8-dinitropyrene	1,8-dinitropyrene results in increased expression of TIPARP mRNA	21887816
D020001	1-Butanol	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
C051246	1-methylanthracene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of TIPARP mRNA	28329830
C548651	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of TIPARP mRNA	19933214
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of TIPARP mRNA	19095052
C087667	2,3,3',4,4',5-hexachlorobiphenyl	2,3,3',4,4',5-hexachlorobiphenyl results in increased expression of TIPARP mRNA	29738842
C070055	2,3',4,4',5-pentachlorobiphenyl	2,3',4,4',5-pentachlorobiphenyl results in increased expression of TIPARP mRNA	29738842
C038890	2,3,4,7,8-pentachlorodibenzofuran	2,3,4,7,8-pentachlorodibenzofuran results in increased expression of TIPARP mRNA	29738842
C038890	2,3,4,7,8-pentachlorodibenzofuran	2,3,4,7,8-pentachlorodibenzofuran results in increased expression of TIPARP mRNA	21724226; 24046277; 29738842;
C014211	2,3,7,8-tetrachlorodibenzofuran	2,3,7,8-tetrachlorodibenzofuran affects the expression of TIPARP mRNA	18343893
C014211	2,3,7,8-tetrachlorodibenzofuran	2,3,7,8-tetrachlorodibenzofuran results in increased expression of TIPARP mRNA	20702594
C014211	2,3,7,8-tetrachlorodibenzofuran	2,3,7,8-tetrachlorodibenzofuran results in increased expression of TIPARP mRNA	24046277
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of TIPARP mRNA	29738842
C010914	2,4-diaminotoluene	2,4-diaminotoluene results in increased expression of TIPARP mRNA	20713471
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	23625689; 29738842;
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in decreased expression of TIPARP mRNA	23625689; 29704546;
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	29738842
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TIPARP mRNA	19692669; 23146750; 29738842; 29947894;
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl affects the expression of TIPARP mRNA	18042819
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TIPARP mRNA	20702594; 23994337;
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TIPARP mRNA	29738842
C035207	4-amino-2,6-dinitrotoluene	4-amino-2,6-dinitrotoluene affects the expression of TIPARP mRNA	21346803
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of TIPARP mRNA	19191707
C012606	4-vinyl-1-cyclohexene dioxide	4-vinyl-1-cyclohexene dioxide affects the expression of TIPARP mRNA	20829426
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TIPARP mRNA	19150397
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of TIPARP mRNA	20382639
D015124	8-Bromo Cyclic Adenosine Monophosphate	8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TIPARP mRNA	22079614
C496492	abrine	abrine results in increased expression of TIPARP mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of TIPARP mRNA	21420995
D000082	Acetaminophen	Acetaminophen affects the expression of TIPARP mRNA	17562736
C106812	adefovir dipivoxil	adefovir dipivoxil results in increased expression of TIPARP mRNA	25596134
D000336	Aerosols	Aerosols results in increased expression of TIPARP mRNA	29501877
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of TIPARP gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of TIPARP mRNA	19770486
D000393	Air Pollutants	Air Pollutants results in increased expression of TIPARP mRNA	18079490
D000395	Air Pollutants, Occupational	Air Pollutants, Occupational results in increased expression of TIPARP mRNA	23195993
D000447	Aldehydes	Aldehydes results in increased expression of TIPARP mRNA	25014914
C011512	alpha-naphthoflavone	alpha-naphthoflavone results in decreased expression of TIPARP mRNA	18762178
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of TIPARP mRNA	24449571
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of TIPARP mRNA	20458559
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of TIPARP mRNA	18687144
D001280	Atrazine	Atrazine results in increased expression of TIPARP mRNA	29505797
D001507	Beclomethasone	Beclomethasone results in increased expression of TIPARP mRNA	23656298
C030935	benz(a)anthracene	benz(a)anthracene results in increased expression of TIPARP mRNA	23656968
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the expression of TIPARP mRNA	21714911
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of TIPARP mRNA	20064835; 20106945; 21802500; 21887816; 22178795; 24472612; 30453624;
D001564	Benzo(a)pyrene	AHR affects the reaction [Benzo(a)pyrene results in increased expression of TIPARP mRNA]	21995607
D001564	Benzo(a)pyrene	Benzo(a)pyrene promotes the reaction [AHR protein binds to TIPARP promoter]	21995607
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of TIPARP mRNA	19770486; 20713471; 21569818; 21715664; 21995607;
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in increased expression of TIPARP mRNA	26377693
C022921	benzo(k)fluoranthene	benzo(k)fluoranthene results in increased expression of TIPARP mRNA	24472612
C022921	benzo(k)fluoranthene	benzo(k)fluoranthene results in increased expression of TIPARP mRNA	26377693
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in increased expression of TIPARP mRNA	23994337
D001663	Bilirubin	Bilirubin results in increased expression of TIPARP mRNA	20196124
C006780	bisphenol A	bisphenol A affects the expression of TIPARP mRNA	21786754
C006780	bisphenol A	bisphenol A results in decreased expression of TIPARP mRNA	27685785; 29275510;
C006780	bisphenol A	[bisphenol A co-treated with Testosterone] results in increased expression of TIPARP mRNA	26496021
C006780	bisphenol A	bisphenol A results in decreased expression of TIPARP mRNA	30816183
C018475	butyraldehyde	butyraldehyde results in increased expression of TIPARP mRNA	26079696
C584509	C646 compound	C646 compound results in increased expression of TIPARP mRNA	26191083
D019256	Cadmium Chloride	Cadmium Chloride affects the expression of TIPARP mRNA	25596134
D002117	Calcitriol	Calcitriol results in increased expression of TIPARP mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of TIPARP mRNA	21592394
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of TIPARP mRNA	31150632
D002251	Carbon Tetrachloride	schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of TIPARP mRNA]	31150632
D000068579	Celecoxib	Celecoxib results in decreased expression of TIPARP mRNA	28201806
C004656	chloroacetaldehyde	chloroacetaldehyde results in decreased expression of TIPARP mRNA	25596134
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in increased expression of TIPARP mRNA	25270620
C100187	chloropicrin	chloropicrin results in increased expression of TIPARP mRNA	26352163
D002737	Chloroprene	Chloroprene results in increased expression of TIPARP mRNA	23125180
D002746	Chlorpromazine	Chlorpromazine results in increased expression of TIPARP mRNA	25596134
D000077404	Cidofovir	Cidofovir results in increased expression of TIPARP mRNA	25596134
D002922	Ciguatoxins	Ciguatoxins affects the expression of TIPARP mRNA	18353800
D002945	Cisplatin	Cisplatin results in decreased expression of TIPARP mRNA	25596134
D002945	Cisplatin	Cisplatin results in increased expression of TIPARP mRNA	27594783
D004002	Clodronic Acid	Clodronic Acid results in increased expression of TIPARP mRNA	25596134
C018021	cobaltous chloride	cobaltous chloride results in increased expression of TIPARP mRNA	19376846
D019327	Copper Sulfate	Copper Sulfate results in increased expression of TIPARP mRNA	19549813
D003513	Cycloheximide	AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]	12147270
D003513	Cycloheximide	Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D003513	Cycloheximide	Cycloheximide results in increased expression of TIPARP mRNA	12147270
D016572	Cyclosporine	Cyclosporine affects the expression of TIPARP mRNA	25596134
D016572	Cyclosporine	Cyclosporine results in decreased expression of TIPARP mRNA	20106945
D016572	Cyclosporine	Cyclosporine results in decreased expression of TIPARP mRNA	19770486
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
C010902	decabromobiphenyl ether	decabromobiphenyl ether analog results in increased expression of TIPARP mRNA	26854739
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of TIPARP mRNA]	27941970
D003907	Dexamethasone	Dexamethasone results in increased expression of TIPARP mRNA	25047013
C041517	dibenzo(a,l)pyrene	dibenzo(a,l)pyrene results in decreased expression of TIPARP mRNA	25908611
C023614	dibenzofuran	dibenzofuran analog results in increased expression of TIPARP mRNA	20566336
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of TIPARP mRNA	21266533
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of TIPARP mRNA	25242112
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of TIPARP mRNA	29581250
D004237	Diuron	Diuron results in increased expression of TIPARP mRNA	21551480; 25152437;
C118739	entinostat	entinostat results in decreased expression of TIPARP mRNA	26272509
C472787	erucylphospho-N,N,N-trimethylpropylammonium	erucylphospho-N,N,N-trimethylpropylammonium results in increased expression of TIPARP mRNA	29464035
D004958	Estradiol	Estradiol affects the expression of TIPARP mRNA	14699072
D004958	Estradiol	[Estradiol binds to ESR2 protein] which results in increased expression of TIPARP mRNA	20404318
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in increased expression of TIPARP mRNA	20660070
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of TIPARP mRNA	19619570
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in increased expression of TIPARP mRNA	30165855
D004958	Estradiol	Estradiol results in increased expression of TIPARP mRNA	19619570; 23019147; 25321415;
D000431	Ethanol	Ethanol results in increased expression of TIPARP mRNA	29361514
D000431	Ethanol	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of TIPARP mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of TIPARP mRNA	17942748
D011345	Fenofibrate	Fenofibrate results in increased expression of TIPARP mRNA	25596134
C007738	fluoranthene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of TIPARP mRNA	28329830
C007738	fluoranthene	fluoranthene results in increased expression of TIPARP mRNA	28329830
C007738	fluoranthene	fluoranthene results in increased expression of TIPARP mRNA	25268939
C007738	fluoranthene	TNF protein inhibits the reaction [fluoranthene results in increased expression of TIPARP mRNA]	25268939
D005485	Flutamide	Flutamide results in increased expression of TIPARP mRNA	24793618
D005557	Formaldehyde	Formaldehyde results in decreased expression of TIPARP mRNA	20655997
D005742	Gasoline	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D005742	Gasoline	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D005839	Gentamicins	Gentamicins results in increased expression of TIPARP mRNA	22061828
D005947	Glucose	TIPARP protein results in increased secretion of Glucose	20876576
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of TIPARP mRNA	20044591
C031927	hydroquinone	hydroquinone results in increased expression of TIPARP mRNA	23416264
D007052	Ibuprofen	Ibuprofen results in increased expression of TIPARP mRNA	25596134
C075954	indolo(3,2-b)carbazole	indolo(3,2-b)carbazole results in increased expression of TIPARP mRNA	18762178
C075954	indolo(3,2-b)carbazole	indolo(3,2-b)carbazole results in increased expression of TIPARP mRNA	23994337
D007213	Indomethacin	Indomethacin results in decreased expression of TIPARP mRNA	28201806
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TIPARP mRNA	25613284
C040507	isobutyl alcohol	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
C067713	lactacystin	lactacystin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D007854	Lead	Lead affects the expression of TIPARP mRNA	28903495
D000077339	Leflunomide	Leflunomide results in increased expression of TIPARP mRNA	28988120
C482199	lipopolysaccharide, E coli O55-B5	lipopolysaccharide, E coli O55-B5 results in decreased expression of TIPARP mRNA	24972896
D008154	Lucanthone	Lucanthone results in increased expression of TIPARP mRNA	21148553
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of TIPARP mRNA	26378955
D008687	Metformin	Metformin results in increased expression of TIPARP mRNA	25596134
D008731	Methoxychlor	Methoxychlor affects the expression of TIPARP mRNA	20829426
D008748	Methylcholanthrene	Methylcholanthrene promotes the reaction [AHR protein binds to TIPARP promoter]	20348232
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of TIPARP mRNA	20348232
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of TIPARP mRNA	20713471
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of TIPARP mRNA	28001369
D015735	Mifepristone	Mifepristone results in decreased expression of TIPARP mRNA	17584828
C000622638	MLN7243	MLN7243 results in increased sumoylation of TIPARP protein	31285264
C000627226	momfluorothrin	momfluorothrin results in decreased expression of TIPARP mRNA	28520973
D009243	NAD	TIPARP protein results in increased abundance of NAD	20876576
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of TIPARP mRNA	24389112
C017096	n-butoxyethanol	n-butoxyethanol results in increased expression of TIPARP mRNA	19812364
D009536	Niacinamide	Niacinamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	20876576
D009532	Nickel	Nickel results in increased expression of TIPARP mRNA	23195993
C029938	nickel sulfate	nickel sulfate results in increased expression of TIPARP mRNA	18651567
D009538	Nicotine	Nicotine results in increased expression of TIPARP mRNA	17456735
C558013	NSC 689534	NSC 689534 results in increased expression of TIPARP mRNA	20971185
D010100	Oxygen	Oxygen deficiency results in increased expression of TIPARP mRNA	25596134
C016030	pantogab	pantogab results in increased expression of TIPARP mRNA	17379144
D052638	Particulate Matter	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D052638	Particulate Matter	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D052638	Particulate Matter	Particulate Matter analog results in increased expression of TIPARP mRNA	24472612
D052638	Particulate Matter	Particulate Matter results in increased expression of TIPARP mRNA	15046786; 22178795; 29703138;
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of TIPARP mRNA	18593933
C086401	pentabromodiphenyl ether	pentabromodiphenyl ether analog results in increased expression of TIPARP mRNA	19095052
C086401	pentabromodiphenyl ether	pentabromodiphenyl ether results in increased expression of TIPARP mRNA	26705709
C046012	pentanal	pentanal results in increased expression of TIPARP mRNA	26079696
D010634	Phenobarbital	Phenobarbital affects the expression of TIPARP mRNA	19159669
D010634	Phenobarbital	Phenobarbital results in decreased expression of TIPARP mRNA	23091169
D010634	Phenobarbital	Phenobarbital results in increased expression of TIPARP mRNA	19270015
C006253	pirinixic acid	pirinixic acid results in decreased expression of TIPARP mRNA	25270620
C006253	pirinixic acid	pirinixic acid results in increased expression of TIPARP mRNA	18301758; 18445702;
D010936	Plant Extracts	Plant Extracts results in increased expression of TIPARP mRNA	21297082
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA	29432896
D011205	Povidone	[Silver analog co-treated with Povidone] results in increased expression of TIPARP mRNA	25194297
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in increased expression of TIPARP mRNA	28903501
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in increased expression of TIPARP mRNA	20660070
D011374	Progesterone	Progesterone results in increased expression of TIPARP mRNA	21795739
C005556	propionaldehyde	propionaldehyde results in increased expression of TIPARP mRNA	26079696
D011691	Puromycin	Puromycin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
C502851	quinocetone	quinocetone results in decreased expression of TIPARP mRNA	27046791
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with ESR1 protein] results in increased expression of TIPARP mRNA	19059307
D000077154	Rosiglitazone	Rosiglitazone results in increased expression of TIPARP mRNA	25596134
C015499	schizandrin B	schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of TIPARP mRNA]	31150632
D012822	Silicon Dioxide	Silicon Dioxide analog results in increased expression of TIPARP mRNA	25895662
D012822	Silicon Dioxide	Silicon Dioxide results in increased expression of TIPARP mRNA	19073995
D012834	Silver	[Silver analog co-treated with Povidone] results in increased expression of TIPARP mRNA	25194297
D012906	Smoke	Smoke results in increased expression of TIPARP mRNA	21095227
C017947	sodium arsenite	sodium arsenite results in increased expression of TIPARP mRNA	29361514
D012999	Soman	Soman results in increased expression of TIPARP mRNA	19281266
D053260	Soot	Soot results in increased expression of TIPARP mRNA	26551751
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of TIPARP mRNA	26378955
D013605	T-2 Toxin	T-2 Toxin results in increased expression of TIPARP mRNA	31299295
D013629	Tamoxifen	[Tamoxifen co-treated with ESR1 protein] results in increased expression of TIPARP mRNA	19059307
D013629	Tamoxifen	Tamoxifen affects the expression of TIPARP mRNA	17555576
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of TIPARP mRNA	15336504
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of TIPARP mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of TIPARP mRNA	21592394
D013739	Testosterone	[bisphenol A co-treated with Testosterone] results in increased expression of TIPARP mRNA	26496021
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA	22403156; 23204111; 30398377;
D013749	Tetrachlorodibenzodioxin	AHR mRNA affects the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	20876576
D013749	Tetrachlorodibenzodioxin	Niacinamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	20876576
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to TIPARP promoter]	20876576
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA	20876576; 26854739;
D013749	Tetrachlorodibenzodioxin	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	23625689; 29738842;
D013749	Tetrachlorodibenzodioxin	AHR gene SNP affects the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	25445724
D013749	Tetrachlorodibenzodioxin	AHR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	29274782
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of TIPARP mRNA	19619570
D013749	Tetrachlorodibenzodioxin	MACROD1 protein inhibits the reaction [TIPARP protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]	25975270
D013749	Tetrachlorodibenzodioxin	MACROD1 protein inhibits the reaction [[TIPARP protein results in increased ADP-ribosylation of and results in decreased activity of AHR protein] which results in decreased susceptibility to Tetrachlorodibenzodioxin]	25975270
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of TIPARP mRNA	22298810
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to TIPARP 3' UTR]	19574409
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to TIPARP promoter]	29274782
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [ARNT protein binds to TIPARP promoter]	29274782
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [ESR1 protein binds to TIPARP 3' UTR]	19574409
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA	17968679; 18762178; 19574409; 19619570; 19692669; 20106945; 20702590; 21496263; 21802500; 22903824; 23625689; 24299737; 24806346; 25445724; 26159488; 27913140; 29274782; 29704546; 29738842; 30096437; 30203000;
D013749	Tetrachlorodibenzodioxin	TIPARP-AS1 promotes the reaction [TIPARP inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]	29274782
D013749	Tetrachlorodibenzodioxin	TIPARP gene SNP affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene SNP affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene SNP affects the susceptibility to Tetrachlorodibenzodioxin	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]	29274782
D013749	Tetrachlorodibenzodioxin	TIPARP mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]	24806346
D013749	Tetrachlorodibenzodioxin	TIPARP mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA]	24806346
D013749	Tetrachlorodibenzodioxin	TIPARP mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]	24806346
D013749	Tetrachlorodibenzodioxin	TIPARP mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]	24806346
D013749	Tetrachlorodibenzodioxin	TIPARP protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP protein results in decreased susceptibility to Tetrachlorodibenzodioxin	25975270
D013749	Tetrachlorodibenzodioxin	AHR affects the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	21995607
D013749	Tetrachlorodibenzodioxin	AHR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270; 19759094;
D013749	Tetrachlorodibenzodioxin	ARNT protein promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D013749	Tetrachlorodibenzodioxin	benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D013749	Tetrachlorodibenzodioxin	Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D013749	Tetrachlorodibenzodioxin	Dactinomycin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D013749	Tetrachlorodibenzodioxin	lactacystin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D013749	Tetrachlorodibenzodioxin	Puromycin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	12147270
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of TIPARP mRNA	18343893; 21570461; 25703434; 26377647;
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin binds to AHR protein] which results in increased expression of TIPARP mRNA	16214954
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to TIPARP gene]	20819909; 21762485;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to TIPARP promoter]	21889950
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA	11716501; 12147270; 15328365; 15652763; 16611356; 16962184; 17942748; 18691609; 18796159; 19759094; 19770486; 19933214; 20159946; 20702590; 20702594; 20819909; 21496263; 21889950; 21995607; 23864506; 23994337; 24806346; 25270620; 25958198; 25975270; 26290441; 27913140; 29738842; 29873790; 31511937;
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]	24806346; 25975270;
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD36 mRNA]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FASN mRNA]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SREBF1 mRNA]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1B1 gene]]	29873790
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA]	29873790
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]	25975270; 29873790;
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]	25975270; 29873790;
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 protein]	25975270
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NFE2L2 mRNA]	29873790
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]	29873790
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA]	29873790
D013749	Tetrachlorodibenzodioxin	TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin	25975270; 29873790;
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of AASS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ABLIM3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ACKR1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ACNAT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ACTA2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ADA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ADM mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of AGA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of AKR1B8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ALG2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ALG8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of AMIGO2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of AMIGO3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ANAPC16 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ANKHD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of APOA5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARFGAP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARFIP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARHGAP32 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARHGAP5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARL13B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARPC1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ARXES1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ASTE1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ATAD2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ATP1B3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ATRIP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of AZIN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of B4GALNT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BAG3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BCL2L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BCL3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BET1L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BHLHE40 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BMP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of BNIP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of C2CD2L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CACFD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CALCRL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CALHM6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CARMIL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CAVIN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CBLL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CBX8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCDC130 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCDC137 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCND1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCNE1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCNE2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CCNT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CD55 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CDK20 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CDKN2AIPNL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CFLAR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CHAC1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CHCHD8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CHD7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CHST12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CKS1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CKS2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CLEC4G mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CLN8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CLP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CNTRL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of COG3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of COG6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CPEB3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CPTP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CRCP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CREB3L2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CSRP3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CXCL12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CYP2B10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of CYP4A14 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DCBLD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DCUN1D3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DDA1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DDX19B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DLL4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DPY19L3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of DUSP7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ECI2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EDNRA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EEF1E1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EFHD2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EHD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EIF1AD mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EIF2AK3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EIF2B4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ELL2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ELL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ELOB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EOGT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ERG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ERO1L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ESAM mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ETNK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ETS1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of EXOG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of F8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FAM107A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FBRS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FCER1G mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FCGR4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FDPS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FH1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FHL4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FKBP14 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FKBP5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FKBPL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FLOT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FOXA2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of FOXA3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GAS6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GCK mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GDA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GDE1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GFPT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GFRA1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GGT6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GIMAP9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GIN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GMPPB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GOLGA3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GOLPH3L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GOLT1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GORASP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GOT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GPR182 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GPT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GRN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GTF2A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of GYS1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of H1F3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of H2AC4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of H2AW mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of H2BC12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HDC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HECW2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HEG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HGSNAT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HHIP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HIP1R mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HOPX mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of HS3ST3B1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ICAM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ID3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IDH3A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IFNGR2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IFRD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IL15RA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IL17RA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IL2RG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of INHBE mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IPPK mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IRAK1BP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IREB2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ISG20 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IVNS1ABP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of JAM2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of JKAMP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of JMJD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of JUP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of KCTD7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of KLF10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of KLHL2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of LASS6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of LCN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of LENG9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of LIG4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of LIN52 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of LPIN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAD1L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAD2L1BP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAN2A1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAP3K5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAP3K6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MAPK14 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MARCO mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MCART1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MCL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MCM4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MED18 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MED31 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MFSD2A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MIDN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MIS12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MLX mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MMGT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MMGT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MRPL22 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MRPL51 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MS4A4B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MYCT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MYD88 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of MYLIP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NAMPT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NAPB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NCEH1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NDEL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NFXL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NFYB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NGDN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NIP7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NNMT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NOSTRIN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NRAS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NRG4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NUAK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of NUDCD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OGFRL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OLFR1039 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OLFR138 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OLFR153 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OLFR569 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OLFR720 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ORAI2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ORC2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of OTOS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PAFAH1B2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PALMD mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PAQR3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PARP4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PBX3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PCID2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PCSK5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PDCD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PDCL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PDE12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PDE1A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PECAM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PER1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PFKFB2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PFKFB3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PHLDA2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PHLDB2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLA1A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLA2G7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLCB4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLEKHF1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLIN3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLK3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PLXNB1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PMS2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PNPLA2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of POFUT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of POLE4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of POLM mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of POLR1E mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of POMGNT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PPIP5K2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PPME1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PRKCH mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PROX1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PRPF3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PTPN12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PTPN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PTPRJ mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PUS7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAB27A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAB2B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAB3A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAB3GAP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RABL6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAD17 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RAPGEF5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RASL11B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RASSF4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RBSN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RDH13 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RDH9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RGP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RHBDD2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RINT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RNF145 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RNF185 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RNF24 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RRP8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RSPRY1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of RUSC1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of S1PR5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SAA1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SCAMP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SCARA5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SDS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SELP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SEPTIN10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SERPINA3F mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SERPINA3K mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SERPINA7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SERTAD3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SH3BP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SIAH2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SIK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC10A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC16A10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC25A32 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC30A5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC35A4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC37A4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC39A14 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC39A6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC41A1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC43A1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC7A5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC9A3R1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SNHG5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SNX10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SP4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SPTY2D1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SRGN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SRM mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ST3GAL5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of STAB2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of STAP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of STAT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of STEAP4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SULT1A1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SURF2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TACC1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TACC2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TAF9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TBC1D8B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TBCCD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TEK mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TGM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TICAM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TIFA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TINF2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMC7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMED3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM167B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM18 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM39A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM41A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM47 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM50B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMEM87B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TMTC2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TNFRSF11B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TOLLIP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TOMM7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TPD52 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TRAK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TRAPPC2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TRIM24 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TRIM3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TRNT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TTI2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TTLL4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TTPAL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of TXNDC11 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UAP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UBE2G2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UBIAD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UBL4A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UFSP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UGCG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of UXT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of VAMP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of VAMP5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of VASN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of VCAM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of VMN1R58 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of VPS37C mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of WDR45B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of YOD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of YRDC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZBTB7B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZBTB8A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFAND2A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP119A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP142 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP143 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP27 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP324 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP329 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP40 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP442 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP53 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP595 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP658 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP748 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP788 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP790 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP933 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP938 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP943 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP947 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP948 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFP9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFPL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZFYVE21 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZNRD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZSCAN22 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ZSWIM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ABCA8B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ABCB4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ABCD2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ABHD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ABHD5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ACACB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ACAD8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ACOT3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ACPP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ACTN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ACTR6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADAM12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADCY9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADGRG3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADGRL2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ADRA1A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of AHI1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of AHRR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ALDH3B1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ALOX12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of AMOT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ANP32A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ANTXR2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of AOX1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of AQP8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ARHGEF10L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ARL5A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ARL6IP5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ARSG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ATG2B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ATOH8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ATXN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of B3GALNT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of B3GNT2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of BCAR1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of BCL2L11 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of BMF mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of BPTF mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of BTRC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CAR2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CASP6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CAV1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CBR3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CCDC93 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CCL28 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CCNG2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CCS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CDC14B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CDC42BPB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CDH2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CDKN1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CHDH mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CHKA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CLDN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CNNM3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of COL15A1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CPEB4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CREB3L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CRTC3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CRYBG3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CSE1L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CTH mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CTRB1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CXADR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CXCL2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CXCR5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CXCR7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CXXC5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CYFIP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CYP1A1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CYP1A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CYP1B1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CYP2G1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of CYP8B1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DAG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DAPK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DCLK3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DCLRE1C mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DCTN6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DDC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DDIT4L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DDX58 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DENN2B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DEPTOR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DHDH mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DHRS9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DHTKD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DIPK1A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DNA2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DNAJB3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DNAJB4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DNAJB8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DNMT3A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DSC2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of DTX4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ECEL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EHBP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EID3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EML4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ENDOU mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ENTPD2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ENTPD5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EPGN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EPS8L2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ERBB3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EREG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ERMP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ETNPPL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ETV6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EVI5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of EXOC3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FABP12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FABP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FAM129B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FBXO21 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FBXW9 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FDX1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FGD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FGF21 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FGF23 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FGFR3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FMO1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FMO2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FMO3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FOXO3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FPGS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FRMD8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FUT4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FZD7 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of FZD8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of G6PC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GADD45B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GADD45G mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GCC1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GCKR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GCLC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GCLM mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GFER mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GPR157 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GPR183 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GRAMD1C mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GRAMD3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GRAMD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GRPEL2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of GTF2I mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HACL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HDAC5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HES6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HILPDA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HIVEP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HJV mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HNF1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HPGD mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HSD17B2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HSPA2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of HTATIP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of IGFBP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of IGSF3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of IKBKG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of IL1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of INSL6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of IRAK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of JAG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of JOSD1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of KANK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of KANK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of KBTBD12 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of KCNK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of KDM3A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of KLB mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LDB1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LDLR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LDOC1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LGALS4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LNX2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LPAR6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LPCAT3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LPIN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LPL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LRAT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LRP4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LRRC8D mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of LRTM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MAFF mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MANBA mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MAPK15 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MAPRE3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MEIG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MEIS2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of METTL27 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MGLL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MICU2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MINDY1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MREG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MSRB3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MTNR1A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MYC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MYO1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of MYOM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NAGS mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NDRG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NDST1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NEK2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NEURL3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NFE2L2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NME5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NOMO1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NOTCH1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NPC1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NPTX1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NQO1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NR2C1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NR5A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NRIP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of NUP155 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OCLN mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR1055 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR111 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR1252 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR1283 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR1300-PS1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR1393 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR1417 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR33 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR402 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR435 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR481 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR493 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR608 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR610 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR646 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR670 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR68 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of OLFR943 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PCP4L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PDK4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PDPK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PGAP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PGD mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PHOSPHO1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PIGC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PIGX mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PIK3R3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PIR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PJA1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PLA2G12A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PLCG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PML mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PMM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PPARD mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PPFIBP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PPNR mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PPP1R3C mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PPP1R9A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PPP2R5A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PREP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PRPF6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PTGES mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PTP4A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of PUM2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of RAB36 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of RHPN2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of RNF125 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of RXRG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of RYR3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of S1PR1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of S1PR3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SAMD4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SAP30 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SCARB1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SCPEP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SEC16A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SELENBP1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SELENBP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SELENOI mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SERP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SERPINE1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SETD3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SGK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SGPL1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SH3PXD2A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SHROOM1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SHROOM3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SIGMAR1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SIPA1L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC17A8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC18A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC1A4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC25A28 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC25A42 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC25A45 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC25A46 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC34A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC35D1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC35F5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC35G1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC46A3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC66A2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC6A6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SMAD3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SMCP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SOCS3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SOX17 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SRPK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SRSF10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SRXN1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SSBP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ST8SIA1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ST8SIA3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of STARD13 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of STAT5B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of STAT6 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of STEAP3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of STRBP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SUN3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SYNE1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TAPT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TAS2R117 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TBC1D16 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TBC1D1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TBC1D31 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TBC1D8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TBCEL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TCF7L2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TEC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TERT mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TLE1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TM4SF4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TMCC3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TNC mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TNFAIP2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TNFAIP8L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TNFRSF10B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TNFRSF18 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TNFRSF19 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TOR1B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TPPP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TRAF5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TRIM2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TRIT1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TSHZ1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TSSK1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TTC28 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TUBA8 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TUBB2A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TWSG1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TXNIP mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of TXNL4A mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UBE2H mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UGDH mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UGT1A10 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UGT2B35 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UHRF1BP1L mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UNC5B mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of USP6NL mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of UVRAG mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of VMN1R49 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of WDR91 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of YPEL2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZDHHC25 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFHX3 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFP28 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFP296 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFP36L1 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFP457 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFP672 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZFP78 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of ZMIZ2 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]	29738842
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA	18796159; 21215274; 21496263; 21724226; 22342509; 24046277; 24355419; 26232522; 27913140; 28433708; 29738842;
C582340	tetradecabromodiphenoxybenzene	tetradecabromodiphenoxybenzene analog results in increased expression of TIPARP mRNA	26854739
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TIPARP mRNA	25613284
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of TIPARP mRNA	22363418; 27404394; 27865774; 28065790; 29501877; 30291989;
C483909	torcetrapib	torcetrapib results in increased expression of TIPARP mRNA	23228038
D014212	Tretinoin	Tretinoin results in increased expression of TIPARP mRNA	21934132; 23724009;
D014212	Tretinoin	Tretinoin results in increased expression of TIPARP mRNA	20488242
C011559	tributyltin	tributyltin results in increased expression of TIPARP mRNA	29505797
C012589	trichostatin A	trichostatin A affects the expression of TIPARP mRNA	28542535
D014260	Triclosan	Triclosan results in decreased expression of TIPARP mRNA	30510588
D014415	Tunicamycin	Tunicamycin results in increased expression of TIPARP mRNA	17127020
D014520	Urethane	Urethane results in increased expression of TIPARP mRNA	28818685
D014635	Valproic Acid	Valproic Acid results in decreased methylation of TIPARP gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of TIPARP mRNA	24935251; 29154799;
D001335	Vehicle Emissions	Vehicle Emissions results in increased expression of TIPARP mRNA	15046786
D001335	Vehicle Emissions	Vehicle Emissions affects the methylation of TIPARP gene	25560391
C025643	vinclozolin	vinclozolin affects the expression of TIPARP mRNA	19015723
C025643	vinclozolin	vinclozolin results in decreased expression of TIPARP mRNA	20566332
D024483	Vitamin K 3	Vitamin K 3 affects the expression of TIPARP mRNA	20044591
D024483	Vitamin K 3	Vitamin K 3 affects the expression of TIPARP mRNA	20829426
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of TIPARP mRNA	18593933
D000077211	Zoledronic Acid	Zoledronic Acid results in increased expression of TIPARP mRNA	24714768; 25596134;

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0013	ADP-ribosylation
KW-0328	Glycosyltransferase
KW-0479	Metal-binding
KW-0520	NAD
KW-0539	Nucleus
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0808	Transferase
KW-0862	Zinc
KW-0863	Zinc-finger

Interpro

InterPro ID	InterPro Term
IPR012317	Poly(ADP-ribose)pol_cat_dom
IPR004170	WWE-dom
IPR037197	WWE_dom_sf
IPR000571	Znf_CCCH

PROSITE

PROSITE ID	PROSITE Term
PS51059	PARP_CATALYTIC
PS50918	WWE
PS50103	ZF_C3H1

Pfam

Pfam ID	Pfam Term
PF00644	PARP

Gene: TIPARP

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction